Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines
- PMID: 35023191
- PMCID: PMC9015557
- DOI: 10.1002/jmv.27588
Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines
Abstract
Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide as an Omicron variant. This variant is a heavily mutated virus and designated as a variant of concern by the World Health Organization (WHO). WHO cautioned that the Omicron variant of SARS-CoV-2 held a very high risk of infection, reigniting anxieties about the economy's recovery from the 2-year pandemic. The extensively mutated Omicron variant is likely to spread internationally, posing a high risk of infection surges with serious repercussions in some areas. According to preliminary data, the Omicron variant of SARS-CoV-2 has a higher risk of reinfection. On the other hand, whether the current COVID-19 vaccines could effectively resist the new strain is still under investigation. However, there is very limited information on the current situation of the Omicron variant, such as genomics, transmissibility, efficacy of vaccines, treatment, and management. This review focused on the genomics, transmission, and effectiveness of vaccines against the Omicron variant, which will be helpful for further investigation of a new variant of SARS-CoV-2.
Keywords: SARS coronavirus; coronavirus; disease control; immune responses; vaccines/vaccine strains; virus classification.
© 2022 Wiley Periodicals LLC.
Conflict of interest statement
The authors declare that there are no conflict of interests.
Figures
Similar articles
-
Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review.Int J Biol Sci. 2022 Jul 11;18(12):4629-4641. doi: 10.7150/ijbs.73583. eCollection 2022. Int J Biol Sci. 2022. PMID: 35874952 Free PMC article.
-
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.Clin Microbiol Rev. 2022 Sep 21;35(3):e0001422. doi: 10.1128/cmr.00014-22. Epub 2022 Jun 6. Clin Microbiol Rev. 2022. PMID: 35862736 Free PMC article. Review.
-
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633. Elife. 2022. PMID: 36004719 Free PMC article.
-
SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask.Yonsei Med J. 2022 Nov;63(11):977-983. doi: 10.3349/ymj.2022.0383. Yonsei Med J. 2022. PMID: 36303305 Free PMC article. Review.
-
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16. J Virol. 2022. PMID: 35972290 Free PMC article.
Cited by
-
The correlated factors of anxiety and depression among Chinese hospital staff during the COVID-19 local outbreak.Medicine (Baltimore). 2024 Oct 25;103(43):e40190. doi: 10.1097/MD.0000000000040190. Medicine (Baltimore). 2024. PMID: 39470563 Free PMC article.
-
In-silico evaluation of the T-cell based immune response against SARS-CoV-2 omicron variants.Sci Rep. 2024 Oct 25;14(1):25413. doi: 10.1038/s41598-024-75658-w. Sci Rep. 2024. PMID: 39455652 Free PMC article.
-
Spectrum of retinal microvascular ischemia in patients with COVID-19 based on multimodal imaging.Heliyon. 2024 Sep 28;10(19):e38535. doi: 10.1016/j.heliyon.2024.e38535. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39430536 Free PMC article.
-
The short-term and long-term prognosis of discharged COVID-19 patients in Guangdong during the first wave of pandemic.Sci Rep. 2024 Oct 14;14(1):23994. doi: 10.1038/s41598-024-76013-9. Sci Rep. 2024. PMID: 39402204 Free PMC article.
-
Structural and genomic evolutionary dynamics of Omicron variant of SARS-CoV-2 circulating in Madhya Pradesh, India.Front Med (Lausanne). 2024 Sep 11;11:1416006. doi: 10.3389/fmed.2024.1416006. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39323472 Free PMC article.
References
-
- WHO WHO warns Omicron variant poses ‘very high’ global risk | World Health Organization News. Al Jazeera. Accessed December 13, 2021. https://wwwaljazeeracom/news/2021/11/29/who-covid-omicron-variant-very-h...
-
- CDC . SARS‐CoV‐2 Variant Classifications and Definitions. Centers for Disease Control and Prevention. Accessed December 22, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classificatio...
-
- Torjesen I. COVID‐19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ. 2021;375:n2943. - PubMed
-
- Schrieber M. The scientist in Botswana who identified omicron was saddened by the world's reaction. Goats and Soda. Accessed December 22, 2021. https://www.npr.org/sections/goatsandsoda/2021/12/16/1064856213/the-scie...
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous